Related Experiment Video
Updated: Jul 20, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
Time to response: comparison of fulvestrant and oral endocrine agents
1Cookridge Hospital, Leeds, UK.
Background:
The different pharmacokinetic profiles of the intramuscularly administered antioestrogen fulvestrant and oral endocrine treatments have led to speculation among some physicians that this could result in a delayed time to response (TTR) with fulvestrant.
Patients And Methods:
An analysis of TTR was performed on data from 2 phase III trials comparing fulvestrant and anastrozole as second-line treatments for postmenopausal women with advanced-stage, tamoxifen-resistant breast cancer.
Results:
In a combined analysis of the data from these trials, median TTR was 3.1 months (range, 0.9-33.1 months) for fulvestrant and 3 months (range, 0.7-20.2 months) for anastrozole, although responses were still being noted after 2-3 years of stable disease in some patients. Data were subsequently analyzed from 3 other randomized phase III trials of fulvestrant, anastrozole, and tamoxifen in postmenopausal women. Time to response was also similar between the 3 treatments in these additional analyses.
Conclusion:
Time to response is similar between fulvestrant and oral endocrine treatments, despite pharmacokinetic differences.
Related Concept Videos
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Dose-Response Relationship: Potency and Efficacy
Bioequivalence: Overview
Oral Hypoglycemic Agents: Sulfonylureas
Bioequivalence of Drugs: Drugs with Multiple Indications
Dose-Response Relationship: Overview
